In fact, an untouched VEGF‐A production was observed with vatalanib, a selective VEGFR inhibitor, in both experimental and clinical studies on various cancers including pancreatic carcinoma.39, 40, 41 In our study, vatalanib treatment of pancreatic cancer cells resulted in exactly the same effect on VEGF‐A overproduction as exposure to an A platensis extract did. This evidence concerns the gene KDR and exocrine pancreatic carcinoma.